NO20024646L - Kombinasjonsterapier med vaskul¶r-skadende aktivitet - Google Patents

Kombinasjonsterapier med vaskul¶r-skadende aktivitet

Info

Publication number
NO20024646L
NO20024646L NO20024646A NO20024646A NO20024646L NO 20024646 L NO20024646 L NO 20024646L NO 20024646 A NO20024646 A NO 20024646A NO 20024646 A NO20024646 A NO 20024646A NO 20024646 L NO20024646 L NO 20024646L
Authority
NO
Norway
Prior art keywords
vasculature
combination therapies
taxane
damaging activity
warm
Prior art date
Application number
NO20024646A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024646D0 (no
Inventor
Peter David Davis
Graeme Dougherty
Original Assignee
Angiogene Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007740A external-priority patent/GB0007740D0/en
Priority claimed from GB0013927A external-priority patent/GB0013927D0/en
Priority claimed from GB0014908A external-priority patent/GB0014908D0/en
Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd
Publication of NO20024646D0 publication Critical patent/NO20024646D0/no
Publication of NO20024646L publication Critical patent/NO20024646L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20024646A 2000-03-31 2002-09-27 Kombinasjonsterapier med vaskul¶r-skadende aktivitet NO20024646L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0007740A GB0007740D0 (en) 2000-03-31 2000-03-31 Combination therapy
GB0013927A GB0013927D0 (en) 2000-06-08 2000-06-08 Combination therapy
GB0014908A GB0014908D0 (en) 2000-06-20 2000-06-20 Combination therapy
PCT/GB2001/001317 WO2001074368A1 (fr) 2000-03-31 2001-03-27 Therapies combinees induisant un effet de deterioration vasculaire

Publications (2)

Publication Number Publication Date
NO20024646D0 NO20024646D0 (no) 2002-09-27
NO20024646L true NO20024646L (no) 2002-10-15

Family

ID=27255634

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024646A NO20024646L (no) 2000-03-31 2002-09-27 Kombinasjonsterapier med vaskul¶r-skadende aktivitet

Country Status (23)

Country Link
US (2) US6906048B2 (fr)
EP (1) EP1272199B1 (fr)
JP (1) JP2003528920A (fr)
KR (1) KR20020087456A (fr)
CN (1) CN1430515A (fr)
AT (1) ATE287267T1 (fr)
AU (2) AU2001242581B2 (fr)
BR (1) BR0109672A (fr)
CA (1) CA2402539A1 (fr)
CZ (1) CZ20023228A3 (fr)
DE (1) DE60108489T2 (fr)
EE (1) EE200200565A (fr)
ES (1) ES2236199T3 (fr)
HU (1) HUP0300290A3 (fr)
IL (1) IL151628A0 (fr)
IS (1) IS6558A (fr)
MX (1) MXPA02009604A (fr)
NO (1) NO20024646L (fr)
NZ (1) NZ521025A (fr)
PL (1) PL366379A1 (fr)
PT (1) PT1272199E (fr)
SK (1) SK13912002A3 (fr)
WO (1) WO2001074368A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021392A1 (en) * 2000-03-31 2007-01-25 Davis Peter D Divided dose therapies with vascular damaging activity
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
FR2834641B1 (fr) * 2002-01-14 2005-04-22 Ct Regional De Lutte Contre Le Protection de la neurotoxicite de l'oxaliplatine par administration de calcium et de magnesium
ATE353650T1 (de) * 2002-04-16 2007-03-15 Astrazeneca Ab Kombinationstherapie zur behandlung von krebs
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
FR2848212B1 (fr) * 2002-12-06 2006-10-27 Aventis Pharma Sa Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation
BRPI0411567A (pt) * 2003-06-18 2006-08-01 Angiogene Pharm Ltd uso de zd6126 ou um seu sal farmaceuticamente aceitável e um dentre 5-fu, cpt-11, e 5-fu e cpt-11, composição farmacêutica, kit, e, métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de um cáncer envolvendo um tumor sólido em um animal de sangue quente
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
US9149489B2 (en) * 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
WO2009011861A1 (fr) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Formulations orales pour du picoplatine
WO2009099634A2 (fr) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Picoplatine et amrubicine utilisées dans le traitement du cancer du poumon
TWI492759B (zh) * 2008-03-05 2015-07-21 Otsuka Pharma Co Ltd 膽甾烷醇衍生物之併用用途
WO2010005799A2 (fr) 2008-07-11 2010-01-14 Board Of Regents, The University Of Texas System Nouveaux acétates de 2-désoxy monosaccharides à activité anticancéreuse
KR101106214B1 (ko) * 2011-04-04 2012-01-20 홍오성 감귤 내껍질 분리 장치
EP3939595A1 (fr) 2013-04-05 2022-01-19 Board of Regents, The University of Texas System Esters de 2-désoxy-monosaccharides ayant une activité antiproliférative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1087785A2 (fr) * 1998-06-15 2001-04-04 Arch Development Corporation Combinaison de facteurs radiotherapeutiques et anti-angiogeniques
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
CZ20023231A3 (cs) 2000-03-31 2003-01-15 Angiogene Pharmaceuticals Ltd. Farmaceutické prostředky obsahující činidla poąkozující cévy

Also Published As

Publication number Publication date
US20030166617A1 (en) 2003-09-04
CN1430515A (zh) 2003-07-16
HUP0300290A3 (en) 2005-12-28
PL366379A1 (en) 2005-01-24
HUP0300290A2 (hu) 2003-06-28
ATE287267T1 (de) 2005-02-15
MXPA02009604A (es) 2003-03-10
AU2001242581B2 (en) 2005-03-03
EE200200565A (et) 2004-06-15
US6906048B2 (en) 2005-06-14
CA2402539A1 (fr) 2001-10-11
BR0109672A (pt) 2003-02-04
JP2003528920A (ja) 2003-09-30
WO2001074368A1 (fr) 2001-10-11
PT1272199E (pt) 2005-05-31
DE60108489D1 (de) 2005-02-24
IL151628A0 (en) 2003-04-10
US20050107346A1 (en) 2005-05-19
SK13912002A3 (sk) 2003-05-02
EP1272199A1 (fr) 2003-01-08
ES2236199T3 (es) 2005-07-16
NO20024646D0 (no) 2002-09-27
EP1272199B1 (fr) 2005-01-19
CZ20023228A3 (cs) 2003-01-15
NZ521025A (en) 2005-06-24
IS6558A (is) 2002-09-20
KR20020087456A (ko) 2002-11-22
AU4258101A (en) 2001-10-15
DE60108489T2 (de) 2006-03-30

Similar Documents

Publication Publication Date Title
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
HK1091481A1 (en) Therapeutic agents useful for treating pain
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
BR0009043A (pt) Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
NO20055605L (no) Kombinasjonsprodukter for behandling av sykdommer som omfatter celleprofilerasjon, migrasjon eller apotose av myelomaceller, eller angiogenese
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
HK1071310A1 (en) Combination therapy for the treatment of cancer
SE9900961D0 (sv) Novel compounds
WO2004045593A3 (fr) Polytherapie anticancereuse au moyen d'un compose anticancereux active par gst et d'un autre traitement anticancereux
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
NO20051261L (no) Morfin-6-glukuronidsalt
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
WO2005035500A3 (fr) Agents therapeutiques servant a traiter la douleur
ATE346080T1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof